Dissolution studies of poorly soluble drug nanosuspensions in non-sink conditions

AAPS PharmSciTech

Volumn 14, Issue 2, 2013, Pages 748-756

  Liu, Peng ^a   De Wulf, Odile ^a,b   Laru, Johanna ^c   Heikkilä, Teemu ^c   Van Veen, Bert ^c   Kiesvaara, Juha ^c   Hirvonen, Jouni ^a   Peltonen, Leena ^a   Laaksonen, Timo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b GHENT UNIVERSITY   (Belgium)

^c ORION CORPORATION   (Finland)

Author keywords

dissolution modeling; dissolution testing; nanosuspensions; non sink conditions; wet milling

Indexed keywords

INDOMETACIN;

ARTICLE; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; MATHEMATICAL MODEL; PARTICLE SIZE; PH; PRIORITY JOURNAL; QUALITY CONTROL; SIMULATION; SUSPENSION; VELOCITY;

CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DISCRIMINANT ANALYSIS; HYDROGEN-ION CONCENTRATION; INDOMETHACIN; KINETICS; MODELS, CHEMICAL; NANOSTRUCTURES; NANOTECHNOLOGY; PARTICLE SIZE; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84879112027     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-9960-2     Document Type: Article

References (36)

1. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev. 2010;62:491-502.
2. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 2011;16:354-60.
3. Date AA, Patravale VB. Current strategies for engineering drug nanoparticles. Curr Opin Colloid Interface Sci. 2004;9:222-35.
4. Müller RH, Keck CM. Twenty years of drug nanocrystals: where are we, and where do we go? Eur J Pharm Biopharm. 2012;80:1-3.
5. Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364(1):64-75.
6. Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int J Pharm. 1998;160(2):229-37.
7. Krishna R, Yu L. Biopharmaceutics applications in drug development. 3rd ed. New York: Springer; 2008.
8. Liu P, Rong X, Laru J, Van Veen B, Kiesvaara J, Hirvonen J, et al. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int J Pharm. 2011;411:215-22.
9. Ambrus R, Kocbek P, Kristl J, Sibanc R, Rajkó R, Szabó-Révész P. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. Int J Pharm. 2009;381(2):153-9.
10. Ganta S, Paxton JW, Baguley BC, Garg S. Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. Int J Pharm. 2009;367:179-86.
11. Sylvestre JP, Tang MC, Furtos A, Leclair G, Meunier M, Leroux JC. Nanonization of megestrol acetate by laser fragmentation in aqueous milieu. J Contr Release. 2011;149(3):273-80.
12. Tucker CJ. Real time monitoring of small particle dissolution by way of light scattering. US Patent; 2004.
13. Crisp MT, Tucker CJ, Rogers TL, Williams III RO, Johnston KP. Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. J Contr Release. 2007;117(3):351-9.
14. Peeters K, De Maesschalck R, Bohets H, Vanhoutte K, Nagels L. In situ dissolution testing using potentiometric sensors. Eur J Pharm Sci. 2008;34:243-9.
15. Kayaert P, Li B, Jimidar I, Rombaut P, Ahssini F, Van den Mooter G. Solution calorimetry as an alternative approach for dissolution testing of nanosuspensions. Eur J Pharm Biopharm. 2010;76(3):507-13.
16. Bhardwaj U, Burgess DJ. A novel USP apparatus 4 based release testing method for dispersed systems. Int J Pharm. 2010;388:287-94.
17. Siewert M, Dressman J, Brown CK, Shah VP. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech. 2003;4(1):article 7.
18. Fogler HS. Elements of chemical reaction engineering. 3rd ed. Upper Saddle River: Prentice Hall PTR; 1999.
19. Frössling N. Über die Verdunstung fallender Tropfen. Gerl Beitr Geophys. 1938;52:170-216.
20. Higuchi WI, Hiestand EN. Dissolution rates of finely divided drug powders I. Effect of a distribution of particle sizes in a diffusion-controlled process. J Pharm Sci. 1963;52:67-71.
21. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm. 1989;51:9-17.
22. Wang Y, Abrahamsson B, Lindfors L, Brasseur JG. Comparison and analysis of theoretical models for diffusion-controlled dissolution. Mol Pharm. 2012;9(5):1052-66.
23. Laaksonen T, Liu P, Rahikkala A, Peltonen L, Kauppinen EI, Hirvonen J, et al. Intact nanoparticulate indomethacin in fast-dissolving carrier particles by combined wet milling and aerosol flow reactor methods. Pharm Res. 2011;28(10):2403-11.
24. Cerdeiraa AM, Mazzottib M, Ganderc B. Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability. Int J Pharm. 2010;396:210-8.
25. Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol. 2010;62(11):1569-79.
26. Dolenc A, Kristl J, Baumgartner S, Planinsek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm. 2009;376:204-12.
27. Jamzad S, Fassihi R. Role of surfactant and pH on dissolution properties of fenofibrate and glipizide - a technical note. AAPS PharmSciTech. 2006;7(2):Article 33.
28. Nokhodchi A, Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M. The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J Pharm Pharm Sci. 2005;8(1):18-25.
29. Agata Y, Iwao Y, Miyagishima A, Itai S. Novel mathematical model for predicting the dissolution profile of spherical particles under non-sink conditions. Chem Pharm Bull. 2010;58(4):511-5.
30. Anhalt K, Geissler S, Harms M, Weigandt M, Fricker G. Development of a new method to assess nanocrystal dissolution based on light scattering. Pharm Res. 2012;29(10):2887-901.
31. Dolenc A, Kristl J, Baumgartner S, Planinšek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm. 2009;376:204-12.
32. Van Eerdenbrugh B, Froyen L, Van Humbeeck J, Martens JA, Augustijnsa P, Van den Mooter G. Drying of crystalline drug nanosuspensions - the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci. 2008;35:127-35.
33. Limnell T, Heikkilä T, Santos HA, Sistonen S, Hellstén S, Laaksonen T, et al. Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles. Int J Pharm. 2011;416(1):242-51.
34. Heng D, Cutler DJ, Chan HK, Yun J, Raper JA. What is a suitable dissolution method for drug nanoparticles? Pharm Res. 2008;25(7):1696-701.
35. Gupta A, Gaud RS, Ganga S. Development of discriminating dissolution method for an insoluble drug: nisoldipine. Int J Pharm Tech Res. 2010;2(1):931-9.
36. Sugano K. Theoretical comparison of hydrodynamic diffusion layer models used for dissolution simulation in drug discovery and development. Int J Pharm. 2008;363:73-7.